proton-pump inhibitor

Overview

Proton pump inhibitors (PPIs) are a class of drugs that irreversibly inhibit the hydrogen-potassium ATPase enzyme system (H⁺/K⁺-ATPase) located on the secretory surface of gastric parietal cells. By blocking this "proton pump," PPIs suppress both basal and stimulated gastric acid secretion more effectively than histamine H₂-receptor antagonists. First introduced in the 1980s, PPIs have become among the most widely prescribed medications globally and are the cornerstone of treatment for acid-related disorders including gastroesophageal reflux disease (GERD), peptic ulcer disease, Helicobacter pylori eradication regimens, and Zollinger-Ellison syndrome. Common agents in this class include omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, all of which are prodrugs activated by the acidic environment of the parietal cell canaliculus.

Beyond their primary acid-suppressive function, PPIs exert significant effects on the gastrointestinal microenvironment—including alterations in luminal pH, bile acid composition, and the gut microbiome—that have increasingly drawn attention in relation to systemic metabolic and pharmacological consequences. The metabolism of several PPIs depends substantially on the cytochrome P450 enzyme cytochrome P450 family 2 subfamily C member 19 (CYP2C19), making genetic polymorphisms in this enzyme clinically relevant to both PPI efficacy and drug-drug interactions. These broader systemic effects have generated a growing body of research examining PPIs not merely as gastroprotective agents, but as modulators of metabolic, cardiovascular, and pharmacokinetic outcomes.

Focus of Latest Publications

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A multicohort cross-sectional mediation analysis (PMID: 42070114) investigated the association between PPI use and metabolic dysfunction-associated steatotic liver disease (MASLD). The study found that PPI use has been associated with MASLD across multiple study cohorts, with lactic acid bacteria and endogenous ethanol proposed as mediating biological variables. This finding implicates PPI-driven alterations in the gut microbiome—specifically shifts in bacterial clades capable of producing lactic acid and ethanol—as a plausible mechanistic pathway linking chronic acid suppression to hepatic steatosis. The study underscores a growing concern that long-term PPI use may exert metabolic consequences extending well beyond the gastrointestinal tract.

Gastrointestinal Protection During Direct Oral Anticoagulant Therapy

The GUARD-OAC trial (PMID: 41506417) was designed to evaluate whether PPI co-therapy provides meaningful gastrointestinal protection for patients receiving direct oral anticoagulants (DOACs). While PPIs are commonly used in patients on combined antithrombotic therapy or those with elevated bleeding risk, the investigators noted that evidence supporting their benefit specifically in DOAC-treated patients remains limited. This randomized controlled trial was designed to address this evidence gap by prospectively assessing gastrointestinal bleeding outcomes with versus without PPI co-administration, highlighting both the clinical rationale for PPI use in anticoagulated populations and the need for robust trial data.

Drug Absorption and Duodenal Physiology in Older Adults

An exploratory study (PMID: 41759986) examined how chronological age, PPI use, and type 2 diabetes alter the physicochemical properties of duodenal contents during fasting. Parameters including gastric pH, buffer capacity, individual bile acid concentrations, and osmolality were assessed in the descending duodenum. The study's relevance lies in its focus on drug disposition: alterations in these luminal parameters in older PPI users or those with type 2 diabetes may substantially change the absorption kinetics of orally administered drugs in the upper small intestine compared to healthy adults. The co-administration of absorption-modifying excipients such as salcaprozate sodium (SNAC) is particularly pertinent here, as SNAC is used to facilitate oral peptide absorption and its efficacy may be pH-dependent.

Interaction With Oral Semaglutide

A related exploratory study (PMID: 41582648) specifically examined whether PPI co-administration affects HbA1c outcomes in patients with type 2 diabetes receiving oral semaglutide. Since oral semaglutide's absorption is facilitated by salcaprozate sodium in a gastric-pH-dependent manner, PPI-mediated elevation of gastric pH could theoretically alter semaglutide bioavailability. The study found the relationship between PPI use and semaglutide absorption to be unclear, warranting further investigation—particularly given the widespread co-prescription of PPIs in patients with type 2 diabetes.

Cardiovascular Risk and Clopidogrel Interaction

Two studies examined the pharmacodynamic interaction between PPIs and clopidogrel, which is metabolically activated via CYP2C19. Since many PPIs (particularly omeprazole and esomeprazole) are inhibitors of CYP2C19, their co-administration with clopidogrel can reduce the antiplatelet efficacy of clopidogrel and theoretically increase cardiovascular risk.

A study published in Arteriosclerosis, Thrombosis, and Vascular Biology (PMID: 41783931) compared cardiovascular event rates in patients receiving concomitant clopidogrel and PPIs, classified by CYP2C19 inhibitory potency of the specific PPI used. A study in Stroke (PMID: 41766537) further evaluated ischemic event risk in stroke patients co-prescribed clopidogrel with either a PPI or a potassium-competitive acid blocker (P-CAB), finding an increased risk of ischemic events despite potential pharmacodynamic interactions being a known concern. Together, these studies reinforce that the CYP2C19-mediated drug-drug interaction between PPIs and clopidogrel carries real-world clinical significance, particularly in high-risk cardiovascular patients.

GERD Diagnosis and Symptom-Based Assessment

An analysis published in Polish Archives of Internal Medicine (PMID: 41817000) highlighted the limitations of empirical PPI therapy as a diagnostic surrogate for objective GERD. The study noted that routine empirical PPI therapy is often unsatisfactory as an indicator of objectively confirmed gastroesophageal reflux disease, suggesting that symptom resolution with PPI treatment cannot reliably confirm the diagnosis of GERD. This underscores the continued importance of objective diagnostic workup, including endoscopy and pH monitoring, in patients with atypical or refractory symptoms.

PPI Use in Atypical Presentations Mimicking GERD

A case report (PMID: 41817000; PMID: 42036925) described gastric sarcoidosis presenting with symptoms indistinguishable from GERD. Escalated PPI therapy led to symptomatic improvement, and immunosuppression was ultimately not required. This case illustrates both the therapeutic flexibility of PPIs in managing upper gastrointestinal symptoms and the diagnostic pitfalls inherent in relying on empirical PPI response to characterize underlying pathology.

Key Publications

May Lactic acid bacteria and endogenous ethanol mediate proton pump inhibitor-associated MASLD: a multicohort cross-sectional mediation analysis. (Gut microbes, 2026, PMID 42070114): "Proton pump inhibitor (PPI) use has been associated with metabolic dysfunction associated with steatotic liver disease (MASLD) in multiple studies."
May Design and rationale of the GUARD-OAC: A randomized controlled trial evaluating proton pump inhibitor cotherapy for gastrointestinal protection in patients requiring direct oral anticoagulants. (American heart journal, 2026, PMID 41506417): "Proton pump inhibitors (PPIs) are reasonably used during combined antithrombotic therapy or based on individual bleeding risk; nonetheless, evidence supporting their benefit in patients receiving DOAC therapy remains limited."
May Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study. (International journal of clinical pharmacology and therapeutics, 2026, PMID 41582648): "...it is unclear whether PPIs affect the absorption of semaglutide..."
May Chronological age, proton pump inhibitors in older adults, and diabetes in older adults on physicochemical characteristics of contents of the descending duodenum during fasting: An exploratory study. (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2026, PMID 41759986): "Explore the impact of chronological age, proton pump inhibitors (PPIs) in older adults, and Type II diabetes in older adults on pH, buffer capacity, individual bile acid concentrations, and osmolality in the contents of the descending part of the duodenum during fasting, to evaluate whether drug disposition in the upper small intestine of relevant individuals is likely to differ from healthy adults."
May Increased Risk of Ischemic Events in Patients With Stroke Treated With Clopidogrel and a P-CAB or PPI. (Stroke, 2026, PMID 41766537): "Proton pump inhibitors (PPIs) are often coprescribed with clopidogrel, despite potential pharmacodynamic interactions."
May Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency. (Arteriosclerosis, thrombosis, and vascular biology, 2026, PMID 41783931): "Proton pump inhibitors (PPIs) may potentially reduce clopidogrel's antiplatelet effect and increase cardiovascular risk."
Apr Clinical utility of symptom-based assessment as an indicator of objective gastroesophageal reflux disease. (Polish archives of internal medicine, 2026, PMID 41817000): "...routine empirical proton pump inhibitor (PPI) therapy is often unsatisfactory..."
Apr Gastric Sarcoidosis Masquerading as Gastroesophageal Reflux Disease: A Case of Diagnostic Uncertainty and Conservative Management. (The American journal of case reports, 2026, PMID 42036925): "The patient's symptoms improved with escalated proton pump inhibitor therapy; immunosuppression was not required."